Ewing Sarcoma - Pipeline Review, H1 2016

Description: Ewing Sarcoma - Pipeline Review, H1 2016

Summary

‘Ewing Sarcoma - Pipeline Review, H1 2016’, provides an overview of the Ewing Sarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ewing Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ewing Sarcoma
- The report reviews pipeline therapeutics for Ewing Sarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Ewing Sarcoma therapeutics and enlists all their major and minor projects
- The report assesses Ewing Sarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Ewing Sarcoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Ewing Sarcoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ewing Sarcoma pipeline depth and
focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

List of Tables
List of Figures
Introduction
Report Coverage
Ewing Sarcoma Overview
Therapeutics Development
Pipeline Products for Ewing Sarcoma - Overview
Pipeline Products for Ewing Sarcoma - Comparative Analysis
Ewing Sarcoma - Therapeutics under Development by Companies
Ewing Sarcoma - Therapeutics under Investigation by Universities/Institutes
Ewing Sarcoma - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Ewing Sarcoma - Products under Development by Companies
Ewing Sarcoma - Products under Investigation by Universities/Institutes
Ewing Sarcoma - Companies Involved in Therapeutics Development
Astellas Pharma Inc.
Cebiotex, S.L.
Celgene Corporation
EntreChem, S.L.
Exelixis, Inc.
Gradalis Inc.
Ipsen S.A.
Kolltan Pharmaceuticals, Inc.
Merck & Co., Inc.
Merrimack Pharmaceuticals, Inc.
NanoSmart Pharmaceuticals, Inc.
Nanovalent Pharmaceuticals Inc.
NantKwest, Inc.
Novartis AG
Oncomatryx Biopharma, S.L.
Recambio S.L
Shionogi & Co., Ltd.
Sigma-Tau S.p.A.
Tesaro, Inc.
Tokalas, Inc.
Ewing Sarcoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
3BP-227 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cabozantinib s-malate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CEB-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cellular Immunotherapy for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
irinotecan hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress

KIT-SG3227 - Drug Profile
Product Description
Mechanism of Action
R&D Progress

linsitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Monoclonal Antibody Conjugate 1 for Ewing Sarcoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress

niraparib - Drug Profile
Product Description
Mechanism of Action
R&D Progress

NV-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress

OMTX-503 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OMTX-703 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
paclitaxel albumin bound - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pazopanib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pembrolizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
racotumomab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RNAi Gene Therapy to Inhibit EWS and FLI1 for Ewing Sarcoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
roneparstat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-588410 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Ewing Sarcoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SP-2509 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SP-2528 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SP-2577 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TK-216 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YK-4279 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ewing Sarcoma - Recent Pipeline Updates
Ewing Sarcoma - Dormant Projects
Ewing Sarcoma - Discontinued Products
Ewing Sarcoma - Product Development Milestones
Featured News & Press Releases
Oct 09, 2015: Novel compound turns off mutant cancer gene in animals with leukemia
Jul 30, 2015: NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer
Jun 04, 2015: Gradalis Announces Presentation of Data From a Pilot Study of Vigil Cancer Vaccine in Ewing's Sarcoma

Feb 11, 2015: NanoSmart Receives FDA Orphan Drug Designation for ANA-Conjugated Liposomal Doxorubicin for the Treatment of Ewing's Sarcoma

Nov 26, 2012: Possible New Treatment for a Childhood Cancer

Apr 16, 2012: EntreChem's Mithramycin Analog EC-8042 Shows Increased Potency And High Selectivity For Treatment Of Sarcoma

Apr 16, 2012: EntreChem's Mithramycin Shows Increased Potency And Higher Selectivity For Treatment Of Sarcoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Ewing Sarcoma, H1 2016

Number of Products under Development for Ewing Sarcoma - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Investigation by Universities/Institutes, H1 2016

Ewing Sarcoma - Pipeline by Astellas Pharma Inc., H1 2016

Ewing Sarcoma - Pipeline by Cebiotex, S.L., H1 2016

Ewing Sarcoma - Pipeline by Celgene Corporation, H1 2016

Ewing Sarcoma - Pipeline by EntreChem, S.L., H1 2016

Ewing Sarcoma - Pipeline by Exelixis, Inc., H1 2016

Ewing Sarcoma - Pipeline by Gradalis Inc., H1 2016
Ewing Sarcoma - Pipeline by Ipsen S.A., H1 2016
Ewing Sarcoma - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016
Ewing Sarcoma - Pipeline by Merck & Co., Inc., H1 2016
Ewing Sarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016
Ewing Sarcoma - Pipeline by NanoSmart Pharmaceuticals, Inc., H1 2016
Ewing Sarcoma - Pipeline by Nanovalent Pharmaceuticals Inc., H1 2016
Ewing Sarcoma - Pipeline by NantKwest, Inc., H1 2016
Ewing Sarcoma - Pipeline by Novartis AG, H1 2016
Ewing Sarcoma - Pipeline by Oncomatryx Biopharma, S.L., H1 2016
Ewing Sarcoma - Pipeline by Recombio S.L, H1 2016
Ewing Sarcoma - Pipeline by Shionogi & Co., Ltd., H1 2016
Ewing Sarcoma - Pipeline by Sigma-Tau S.p.A., H1 2016
Ewing Sarcoma - Pipeline by Tesaro, Inc., H1 2016
Ewing Sarcoma - Pipeline by Tokalas, Inc., H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Ewing Sarcoma Therapeutics - Recent Pipeline Updates, H1 2016
Ewing Sarcoma - Dormant Projects, H1 2016
Ewing Sarcoma - Discontinued Products, H1 2016
List of Figures
Number of Products under Development for Ewing Sarcoma, H1 2016
Number of Products under Development for Ewing Sarcoma - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

Ordering:

Order Online - [http://www.researchandmarkets.com/reports/3753849/](http://www.researchandmarkets.com/reports/3753849/)
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Ewing Sarcoma - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3753849/
Office Code: SCD2FPEQ

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ______________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

---

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World